Histone Deacetylase Inhibitors in Cancer Therapy
- PMID: 30526462
- DOI: 10.2174/1568026619666181210152115
Histone Deacetylase Inhibitors in Cancer Therapy
Abstract
Histone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of HDACs expression, mutation and/or inappropriate recruitments has been discovered in a broad range of tumors contributing to the tumorigenesis through a serial of biological pathways. HDACs, therefore, are characterized as promising cancer therapeutic targets, and their inhibitors are under rapid development. Here, we discuss HDAC inhibitors in terms of their functional mechanism establishing the anti-tumor effects and potential clinical applications including the synergistic effects in combinational treatment.
Keywords: Cancer treatment; DNA; Epigenetics; Histone Deacetylase; Inhibitors; RNA..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.Curr Protein Pept Sci. 2018;19(3):333-340. doi: 10.2174/1389203718666170106101133. Curr Protein Pept Sci. 2018. PMID: 28059044 Review.
-
Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.Curr Top Med Chem. 2019;19(12):995-1004. doi: 10.2174/1568026619666190125145110. Curr Top Med Chem. 2019. PMID: 30686256 Review.
-
Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.Int J Mol Sci. 2020 Nov 2;21(21):8198. doi: 10.3390/ijms21218198. Int J Mol Sci. 2020. PMID: 33147762 Free PMC article. Review.
-
Epigenetic therapy of cancer with histone deacetylase inhibitors.J Cancer Res Ther. 2014 Jul-Sep;10(3):469-78. doi: 10.4103/0973-1482.137937. J Cancer Res Ther. 2014. PMID: 25313724 Review.
-
An Overview of HDAC Inhibitors and their Synthetic Routes.Curr Top Med Chem. 2019;19(12):1005-1040. doi: 10.2174/1568026619666190227221507. Curr Top Med Chem. 2019. PMID: 30827245 Review.
Cited by
-
HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells.Cancer Immunol Res. 2023 May 3;11(5):657-673. doi: 10.1158/2326-6066.CIR-22-0317. Cancer Immunol Res. 2023. PMID: 36898011 Free PMC article.
-
Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma.Oncogene. 2021 Sep;40(39):5843-5853. doi: 10.1038/s41388-021-01974-4. Epub 2021 Aug 3. Oncogene. 2021. PMID: 34345016 Free PMC article.
-
KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.Breast Cancer Res Treat. 2021 Sep;189(2):347-361. doi: 10.1007/s10549-021-06325-1. Epub 2021 Jul 8. Breast Cancer Res Treat. 2021. PMID: 34240274
-
The potential value of the Purinergic pathway in the prognostic assessment and clinical application of kidney renal clear cell carcinoma.Aging (Albany NY). 2024 Jan 4;16(1):246-266. doi: 10.18632/aging.205364. Epub 2024 Jan 4. Aging (Albany NY). 2024. PMID: 38180750 Free PMC article.
-
Enhancing Transcriptional Reprogramming of Mesenchymal Glioblastoma with Grainyhead-like 2 and HDAC Inhibitors Leads to Apoptosis and Cell-Cycle Dysregulation.Genes (Basel). 2023 Sep 12;14(9):1787. doi: 10.3390/genes14091787. Genes (Basel). 2023. PMID: 37761927 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
